Meadow Creek Investment Management LLC raised its stake in shares of Davita Inc (NYSE:DVA) by 3.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,416 shares of the company’s stock after purchasing an additional 2,848 shares during the period. Meadow Creek Investment Management LLC owned 0.06% of Davita worth $4,974,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Tyers Asset Management LLC increased its position in shares of Davita by 3.3% during the 2nd quarter. Tyers Asset Management LLC now owns 154,728 shares of the company’s stock valued at $8,705,000 after purchasing an additional 4,984 shares during the last quarter. Flinton Capital Management LLC boosted its stake in Davita by 3.3% during the second quarter. Flinton Capital Management LLC now owns 187,884 shares of the company’s stock worth $10,571,000 after buying an additional 6,052 shares during the period. Neuburgh Advisers LLC increased its position in Davita by 3.3% during the second quarter. Neuburgh Advisers LLC now owns 121,572 shares of the company’s stock valued at $6,840,000 after acquiring an additional 3,916 shares during the last quarter. Riverhead Capital Management LLC increased its position in Davita by 3.4% during the second quarter. Riverhead Capital Management LLC now owns 138,406 shares of the company’s stock valued at $7,787,000 after acquiring an additional 4,600 shares during the last quarter. Finally, Pacer Advisors Inc. raised its stake in shares of Davita by 37.7% in the second quarter. Pacer Advisors Inc. now owns 16,987 shares of the company’s stock valued at $956,000 after acquiring an additional 4,651 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.
A number of brokerages have recently issued reports on DVA. Robert W. Baird lowered shares of Davita from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $70.00 to $65.00 in a research note on Friday, July 26th. William Blair downgraded Davita from an “outperform” rating to a “market perform” rating in a report on Wednesday. UBS Group decreased their target price on Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. SunTrust Banks reiterated a “hold” rating and issued a $68.00 target price on shares of Davita in a report on Wednesday. Finally, ValuEngine cut Davita from a “hold” rating to a “sell” rating in a report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $67.31.
DVA stock traded down $2.25 during trading on Wednesday, hitting $59.41. 870,369 shares of the company’s stock traded hands, compared to its average volume of 4,047,611. The firm has a market capitalization of $9.63 billion, a P/E ratio of 16.64, a PEG ratio of 0.58 and a beta of 1.59. Davita Inc has a 1 year low of $43.40 and a 1 year high of $79.11. The company has a quick ratio of 1.10, a current ratio of 1.12 and a debt-to-equity ratio of 1.90. The business has a fifty day simple moving average of $58.24 and a two-hundred day simple moving average of $54.36.
Davita (NYSE:DVA) last posted its earnings results on Thursday, August 1st. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.12. Davita had a return on equity of 14.67% and a net margin of 1.21%. The company had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.86 billion. During the same quarter in the prior year, the business earned $1.05 earnings per share. Davita’s revenue was down 1.5% on a year-over-year basis. On average, equities research analysts predict that Davita Inc will post 4.79 EPS for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: Bond
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.